"Acute heart failure (AHF)"- Market Insights, Epidemiology and Market Forecast-2020

  • ID: 3645171
  • Drug Pipelines
  • Region: Global
  • 64 Pages
  • DelveInsight
1 of 4
The Global AHF Market Was $188 Million in 2015 and Expected to Grow to $929 Million by 2020

FEATURED COMPANIES

  • Amgen
  • Bristol-Myers Squibb
  • Capricor Therapeutics
  • Cardiorentis
  • Novartis Pharmaceuticals
  • Trevena
  • MORE
The Acute heart failure (AHF) - Market Insights, Epidemiology and Market Forecast-2022 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan.

Acute Heart Failure (AHF) is the rapid onset of sign and symptoms of Heart Failure resulting in need and urgent therapy or hospitalization. The AHF primarily includes the symptoms of pulmonary congestion or peripheral perfusion due to cardiac or vascular dysfunction.

Based on the recommended guidelines, loop diuretics are the most common treatment for the Acute Heart Failure in patients with dyspnoea caused by pulmonary oedema, more than 90% of patients admitted with AHF receives this drug.

Key Coverage and Benefits:

- The report will help in developing business strategies by understanding the trends shaping and driving the global Acute heart failure (AHF) market.
- Identifying patient populations in the global Acute heart failure (AHF) market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the best opportunities for Acute heart failure (AHF) therapeutics in each of the markets covered.
- To understand the future market competition in the global Acute heart failure (AHF) therapeutics market and Insightful review of the key market drivers and barriers.

Scope of the Report:

- Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2022.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2022.
- It also provides Acute heart failure (AHF) for United States, EU5 and Japan from 2015 and forecasted Market to 2022.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen
  • Bristol-Myers Squibb
  • Capricor Therapeutics
  • Cardiorentis
  • Novartis Pharmaceuticals
  • Trevena
  • MORE
- Report Introduction
- Executive Summary
- Key findings
- Acute Heart Failure Market Overview at a Glance
- Worldwide Market Size of Acute Heart Failure in 2015 (MM)
- Worldwide Market Size of Acute Heart Failure in 2022 (MM)
- Acute Heart Failure
- Disease Overview
- Treatment Goals
- Management
- Treatment Algorithms
- Epidemiology and Patient Population
- Key Findings
- Overview
- Diagnosed Hospitalization Cases of Acute Heart Failure
- United States
- 5EU and Japan
- Total number of Hospitalization Cases for Acute Heart Failure in 7 Major Markets
- Current Clinical Practice
- Conventional Therapies for Acute Heart Failure Management
- In Cases of Pulmonary Oedema
- In cases of Hypotension and Cardiogenic Shock
- In case of Hypertension
- Treatment after Stabilization
- Acute Novel Therapies
- Carperitide
- Product Profile
- Advantages & Disadvantages
- Cost of Therapy
- Drug Sales
- Carperitide Historical Sales and Forecasted Sales (2015-2022)
- Acute Heart Failure-Global Market Assessment
- Key Findings
- Global Acute Heart Failure Market
- Market Overview
- Global Market Sales by Treatment Setting in AHF, 2015-2022
- Total Acute Heart Failure Drug Sales
- Timeline of Key Market events for Acute Heart Failure
- Acute Heart Failure-United States Market Assessment
- US Market Overview
- United States Market Sales by Treatment Setting in AHF, 2015-2022
- United States Market Share by Treatment Setting in AHF, 2015-2022
- Acute Heart Failure-France Market Assessment
- France Market Overview
- France Market Sales by Treatment Setting in AHF, 2015-2022
- France Market Share by Treatment Setting in AHF, 2015-2022
- Acute Heart Failure-Germany Market Assessment
- Germany Market Overview
- Germany Market Sales by Treatment Setting in AHF, 2015-2022
- Germany Market Share by Treatment Setting in AHF, 2015-2022
- Acute Heart Failure-Italy Market Assessment
- Italy Market Overview
- Italy Market Sales by Treatment Setting in AHF, 2015-2022
- Italy Market Share by Treatment Setting in AHF, 2015-2022
- Acute Heart Failure-Spain Market Assessment
- Spain Market Overview
- Spain Market Sales by Treatment Setting in AHF, 2015-2022
- Spain Market Share by Treatment Setting in AHF, 2015-2022
- Acute Heart Failure-United Kingdom Market Assessment
- United Kingdom Market Overview
- United Kingdom Market Sales by Treatment Setting in AHF, 2015-2022
- United Kingdom Market Share by Treatment Setting in AHF, 2015-2022
- Acute Heart Failure-Japan Market Assessment
- Japan Market Overview
- Japan Market Sales by Treatment Setting in AHF, 2015-2022
- Japan Market Share by Treatment Setting in AHF, 2015-2022
- Market Drivers and Market Constraints
- Factors driving the market for Acute Heart Failure
- Factors constraining the market for Acute Heart Failure
- Emerging Therapies
- Key findings
- Unmet Need
- Pipeline Overview
- Product Profiles (Phase III)
- Ularitide: Cardiorentis
- Product Description:
- Research and Development
- Product Development Activities:
- Serelaxin: Novartis Pharmaceuticals
- Product Description:
- Research and Development
- Product Development Activities:
- Product Profiles (Phase II)
- CXL 1427: Bristol-Myers Squibb
- Product Description:
- Research and Development
- Product Development Activities:
- TRV 027: Trevena
- Product Description:
- Research and Development
- Product Development Activities:
- Omecamtiv mecarbil: Amgen
- Product Description:
- Research and Development
- Product Development Activities:
- Post Acute Heart Failure Management Therapy
- Cenderitide: Capricor Therapeutics
- Product Description:
- Research and Development
- Product Development Activities:
- Side Effects associated with the Emereging Therapies
- Forecasting Outlook
- Global Market size of Acute Heart Failure
- Global Acute Heart Failure Therapy Sales
- Dosage, Days of Therapy and Compliance
- Prices Sources & Assumptions
- Consulting Services
- Disclaimer

List of Tables

- Table 1: Global (7MM) Epidemiology (N)
- Table 2: Total Hospitalizations for Acute HF (Men and Women =45 Years) (2015-2022)
- Table 3: Carperitide Historical Sales and Forecasted Sales (2015-2022) (USD MM)
- Table 4: Global Acute Heart Failure Sales- 2015-2022 (USD MM)
- Table 5: AHF Total Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
- Table 6: Timeline of Key Events in Acute Heart Failure
- Table 7: United States Acute Heart Failure Sales- 2015-2022 (USD MM)
- Table 8: AHF United States Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
- Table 9: France Acute Heart Failure Sales- 2015-2022 (USD MM)
- Table 10: AHF France Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
- Table 11: Germany Acute Heart Failure Sales- 2015-2022 (USD MM)
- Table 12: AHF Germany Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
- Table 13: Italy Acute Heart Failure Sales- 2015-2022 (USD MM)
- Table 14: AHF Italy Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
- Table 15: Spain Acute Heart Failure Sales- 2015-2022 (USD MM)
- Table 16: AHF Spain Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
- Table 17: United Kingdom Acute Heart Failure Sales- 2015-2022 (USD MM)
- Table 18: AHF United Kingdom Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
- Table 19: Japan Acute Heart Failure Sales- 2015-2022 (USD MM)
- Table 20: AHF Japan Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
- Table 21: Side Effects associated with Emerging Therapies (Phase III & Phase II)
- Table 22: Global Market Size of Acute Heart Failure by Country
- Table 23: Global Acute Heart Failure Sales by Therapy
- Table 24: Acute Heart Failure Therapy- Dosage, Days of Therapy and Compliance
- Table 25: Pricing Sources & Assumptions

List of Figures

- Figure 1: Normotensive AHF (SBP 90-140 mmHg)
- Figure 2: Hypotensive AHF (SBP<90mmHg)
- Figure 3: Hypertensive AHF (SBP>140mmHg)
- Figure 4:Diagnosed Hospitalization Cases of Acute Heart Failure in 7 MM-(2015-2022)
- Figure 5: Total Hospitalization Cases and Diagnosed rate for Acute HF (Men and Women =45 Years) (2015-2022)
- Figure 4: Carperitide Historical Sales and Forecasted Sales (2015-2022) (USD MM)
- Figure 1: Global Acute Heart Failure Sales- 2015-2022 (USD MM)
- Figure 2: AHF Global Sales by Treatment Setting- 2015-2022
- Figure 9: AHF Total Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
- Figure 3: United States Acute Heart Failure Sales- 2015-2022 (USD MM)
- Figure 4: AHF United States Sales by Treatment Setting- 2015-2022 (USD MM)
- Figure 5: AHF United States Sales Patient Share by Treatment Setting- 2015-2022 (%)
- Figure 6: France Acute Heart Failure Sales- 2015-2022 (USD MM)
- Figure 7: AHF France Sales by Treatment Setting- 2015-2022 (USD MM)
- Figure 8: AHF France Sales Patient Share by Treatment Setting- 2015-2022 (%)
- Figure 9: Germany Acute Heart Failure Sales- 2015-2022 (USD MM)
- Figure 10: AHF Germany Sales by Treatment Setting- 2015-2022 (USD MM)
- Figure 11: AHF Germany Sales Patient Share by Treatment Setting- 2015-2022 (%)
- Figure 12: Italy Acute Heart Failure Sales- 2015-2022 (USD MM)
- Figure 13: AHF Italy Sales by Treatment Setting- 2015-2022 (USD MM)
- Figure 14: AHF Italy Sales Patient Share by Treatment Setting- 2015-2022 (%)
- Figure 15: Spain Acute Heart Failure Sales- 2015-2022 (USD MM)
- Figure 16: AHF Spain Sales by Treatment Setting- 2015-2022 (USD MM)
- Figure 17: AHF Spain Sales Patient Share by Treatment Setting- 2015-2022 (%)
- Figure 18: United Kingdom Acute Heart Failure Sales- 2015-2022 (USD MM)
- Figure 19: AHF United Kingdom Sales by Treatment Setting- 2015-2022 (USD MM)
- Figure 20: AHF United Kingdom Sales Patient Share by Treatment Setting- 2015-2022 (%)
- Figure 21: Japan Acute Heart Failure Sales- 2015-2022 (USD MM)
- Figure 22: AHF Japan Sales by Treatment Setting- 2015-2022 (USD MM)
- Figure 23: AHF Japan Sales Patient Share by Treatment Setting- 2015-2022 (%)
- Figure 28: Pipeline Trend in Acute Heart Failure
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Amgen
- Bristol-Myers Squibb
- Capricor Therapeutics
- Cardiorentis
- Novartis Pharmaceuticals
- Trevena
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll